NexImmune

Also Clin0 multiple cancers; NEXI-002 Clin1 (paused Aug 2022) multiple myeloma, Clin0 autoimmune diseases; NEXI-003 Clin0/Clin1 HPV cancers, Clin0 infectious diseases; NEXI-004 Clin0 EBV diseases

NexImmune is developing unique T cell immunotherapies for cancer, autoimmune and infectious diseases. Using naturally-occurring biology, NexImmune is orchestrating a targeted cell-mediated immune response across a broad range of diseases through the use of their Artificial Immune Modulation (AIM) technology. AIM nanoparticles act as synthetic immune cells that deliver immune-specific signals to targeted T cells, directing activation or suppression, depending on the indication. The modular approach means the technology can be applied across multiple therapeutic areas, both ex vivo or as injectable products.

Jobs: